Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.24.1
Summary of Significant Accounting Policies (Details Narrative)
$ in Thousands
 12 Months Ended
Dec. 12, 2019
USD ($)
Dec. 31, 2023
USD ($)
Segment
Dec. 31, 2022
USD ($)
Property, Plant and Equipment [Line Items]      
Number of operating segment | Segment   1  
Number of reportable segment | Segment   1  
Cash FDIC insured amount   $ 250  
Accrual for interest or penalties   0  
Cystic Fibrosis Foundation Therapeutics Development Award [Member]      
Property, Plant and Equipment [Line Items]      
Research and development, costs incurred   88 $ 811
Genentech Feasibility Study Agreement [Member]      
Property, Plant and Equipment [Line Items]      
Revenue recognized $ 33 $ 33 $ 0
Three Molecules [Member] | Genentech Feasibility Study Agreement [Member]      
Property, Plant and Equipment [Line Items]      
Revenue recognized $ 100    
Minimum [Member]      
Property, Plant and Equipment [Line Items]      
Leasehold improvements and equipment, useful life   3 years  
Maximum [Member]      
Property, Plant and Equipment [Line Items]      
Leasehold improvements and equipment, useful life   10 years